Inhalable cell membrane-coated silk fibroin nanoparticles, and preparation method and application thereof
By preparing inhaled silk fibroin nanoparticles encapsulated in cell membranes, the problems of systemic drug administration side effects and insufficient drug concentration in the treatment of acute pulmonary spasm were solved, achieving precise drug delivery and targeted delivery to the lungs, thus improving the therapeutic effect.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHEJIANG SCI-TECH UNIV
- Filing Date
- 2026-05-25
- Publication Date
- 2026-07-21
AI Technical Summary
In existing technologies, treatment options for acute pulmonary spasm suffer from side effects due to systemic administration and insufficient drug concentration at the lesion site. Furthermore, existing nanoparticles have a short residence time in the lungs and low targeting efficiency.
By using inhaled cell membrane-encapsulated silk fibroin nanoparticles, drug-loaded silk fibroin nanoparticles are blended with cell membranes and extruded using an extruder to prepare nanoparticles with active targeting capabilities, enabling precise drug delivery to the lungs.
It significantly improved the therapeutic effect of drugs on pulmonary spasm lesions, reduced the side effects of systemic dosage, prolonged the residence time of nanoparticles in the lungs, and achieved precise drug delivery.
Smart Images

Figure CN122424166A_ABST